Boston Scientific is trading at $43.97, with a -4.04% change, amid a sharp broader-market decline; no confirmed company-specific catalyst has emerged. - No new company-specific announcement explaining the November 5 decline surfaced in the search. Healthcare is also down, pointing to a risk-off backdrop. - Third-quarter adjusted EPS was $0.73, below prior guidance of $0.80–$0.82; Boston Scientific lowered its full-year outlook after a cybersecurity disruption. - That earnings news predates this session and is context, not a confirmed cause of today’s move.